IMDx boasts a diverse team, incorporating expertise in finance, law, quality, science, and medicine, who are all involved in shaping products from concept to commercialization. This unique approach sets IMDx apart in the in-vitro diagnostics (IVD) sector.
Recognized for its contributions, IMDx has been named a Business Leader in Medical Diagnostics by Scientific American within the Scientific American 50 and has been honored with a North American Healthcare Innovation Award in molecular diagnostics by Frost & Sullivan. Their last recorded investment stands at $1.61M in debt financing, dating back to 06 August 2014. No specific information about investors has been disclosed.
IMDx's dedication to innovation and its strong position within the evolving IVD industry make it an intriguing prospect for potential investors seeking to capitalize on disruptive technologies in the biotechnology and healthcare sectors.